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Burkholderia pseudomallei, the causative agent of melioidosis, is among a growing
number of bacterial pathogens that are increasingly antibiotic resistant. Antimicrobial
peptides (AMPs) have been investigated as an alternative approach to treat microbial
infections, as generally, there is a lower likelihood that a pathogen will develop resistance
to AMPs. In this study, 36 candidate Caenorhabditis elegans genes that encode
secreted peptides of <150 amino acids and previously shown to be overexpressed
during infection by B. pseudomallei were identified from the expression profile of infected
nematodes. RNA interference (RNAi)-based knockdown of 12/34 peptide-encoding
genes resulted in enhanced nematode susceptibility to B. pseudomallei without affecting
worm fitness. A microdilution test demonstrated that two peptides, NLP-31 and
Y43C5A.3, exhibited anti-B. pseudomallei activity in a dose dependent manner on
different pathogens. Time kill analysis proposed that these peptides were bacteriostatic
against B. pseudomallei at concentrations up to 8× MIC90. The SYTOX green
assay demonstrated that NLP-31 and Y43C5A.3 did not disrupt the B. pseudomallei
membrane. Instead, gel retardation assays revealed that both peptides were able to bind
to DNA and interfere with bacterial viability. In parallel, microscopic examination showed
induction of cellular filamentation, a hallmark of DNA synthesis inhibition, of NLP-31
and Y43C5A.3 treated cells. In addition, the peptides also regulated the expression of
inflammatory cytokines in B. pseudomallei infected macrophage cells. Collectively, these
findings demonstrate the potential of NLP-31 and Y43C5A.3 as anti-B. pseudomallei
peptides based on their function as immune modulators.
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INTRODUCTION
Burkholderia pseudomallei is the causative agent of melioidosis, a fulminant infectious disease
prevalent in Northern Australia and Southeast Asia (Wiersinga et al., 2012). The infection triggers
various clinical manifestations, ranging from asymptomatic infection to severe septicaemia, in
humans and animals. Diagnosis is mainly based on bacterial culture or serological assays whilst
treatment is limited to third-generation cephalosporins or carbapenems. No licensed vaccine is
currently available for melioidosis although efforts to evaluate the use of live attenuated, inactivated
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whole cell and recombinant subunits as vaccine candidates are
ongoing (Sarkar-Tyson and Titball, 2010). In addition, this
pathogen is inherently resistant to a wide range of antimicrobials
including ß-lactams, aminoglycosides, and macrolides (Estes
et al., 2010), and relapse, recrudescence and high fatality rates are
commonly reported even in melioidosis patients administered
appropriate and prolonged antibiotics therapy (Stevens and
Galyov, 2004). Thus, an alternative approach to address the
problem of resistance is the exploitation of antimicrobial peptides
(AMPs).
To date, almost 2000 AMPs have been chemically synthesized
or identified from various organisms including microbes, insects,
invertebrates and mammals (Zhao et al., 2013). They are short,
usually cationic peptides of 10–150 amino acids and serve as
the first line of defense against pathogenic assault (Jenssen
et al., 2006). AMPs have a number of features in common
with antibiotics such as the ability to kill bacterial cells and
target a wide spectrum of bacteria including clinically relevant
antibiotic-resistant pathogens. Whilst antibiotics are susceptible
to degradation by bacterial proteases, AMPs are less likely to be
successfully targeted by proteases because most of these peptides
lack unique epitopes that serve as protease recognition sites
(Zasloff, 2002). Many AMPs are known to act directly on the
pathogen membrane rendering the development of microbial
resistance by mutation less likely (Peschel and Sahl, 2006). Some
AMPs are multi-functional with different targets which lowers
the possibility of the bacteria acquiring resistance by simply
modulating a single target (Marr et al., 2006). Nonetheless,
recent findings have demonstrated that members of the genus
Burkholderia, specifically B. cepacia, are highly resistant to AMPs
including polymyxin B (Loutet et al., 2011). However, AMPs that
are reportedly active against B. pseudomallei include the human
cathelicidin LL-37 and LL-31, defensin HNP-1, histatin and
histatin variants, lactoferrin, bactenecin, cecropin A-magainin
(CA-MA), RTA3 and bovine myeloid antimicrobial peptide-18
(BMAP-18; Kanthawong et al., 2012; Madhongsa et al., 2013).
In an earlier study, expression profiling revealed that a group
of worm genes that were overexpressed during B. pseudomallei
infection included a subset of genes with potential AMP function
(Lee et al., 2013). The nematodeCaenorhabditis elegans is thought
to produce putative AMPs as part of its inducible defense
response toward infection by pathogenic bacteria (Pujol et al.,
2008). In this study, potential AMP-encoding genes were knocked
down by RNAi and the encoding peptide’s antimicrobial function
was assumed if RNAi-treated worms were more susceptible
to infection. Peptides that showed potential were synthesized
and evaluated using the microdilution test and the underlying
mechanism(s) of action of the candidate AMPs as anti-bacterial
agents as well as possible immunomodulators was examined in
the context of a B. pseudomallei infection.
MATERIALS AND METHODS
Bacterial and Nematode Strains
Bacterial strains used were B. pseudomallei R15, Pseudomonas
aeruginosa PA14, Salmonella typhimurium SL1344,
Staphylococcus aureus NCTC8325-4, Methicillin-resistant
S. aureus (MRSA) ATCC 33591, and Enterococcus faecalis
V583. Each bacterial culture was aerobically incubated at 37◦C
unless otherwise stated. The B. pseudomallei Human R15 strain
used in this study is a biofilm-producing clinical isolate from
Malaysia that is pathogenic in the mouse and C. elegans infection
models (Lee et al., 2007, 2011; Eng and Nathan, 2015). All
experiments involving B. pseudomallei were performed in a
Biosafety Level 2+ laboratory. Standard Operating Procedures
for working with pathogens were approved by the Universiti
Kebangsaan Malaysia Animal Ethics Committee (UKMAEC)
and the Institutional Biosafety Committee. For RNAi feeding,
individual C. elegans RNAi clones were selected from the
Ahringer library (Geneservice, UK; Fraser et al., 2000; Kamath
et al., 2003) and the Vidal library (Open Biosystem, USA; Rual
et al., 2004). All plasmids were transformed into Escherichia
coli HT115 (DE3), an RNase III-deficient E. coli strain with
isopropyl β-D-1-thiogalactopyranoside (IPTG) inducible T7
polymerase activity (Timmons et al., 2001). RNAi sensitive
double mutant worms glp-4(bn2);rrf-3(pk1426) were obtained
from the Caenorhabditis Genetics Centre (CGC). Worms were
propagated at 16◦C on nematode growth medium (NGM) agar
pre-seeded with E. coli OP50 as the food source.
Preparation of RNAi-Treated Worms
Gene silencing was performed as previously described (Lee et al.,
2013), albeit with minor modifications. Briefly, the axenised eggs
of glp-4(bn2);rrf-3(pk1426) double mutant worms were spotted
onto the bacterial lawn of E. coli HT115 expressing dsRNA.
The NGM agar plates were supplemented with 100 µg/ml
carbenicillin and 1 mM IPTG for RNAi induction. Eggs were
allowed to hatch and develop into adult worms over 72 h at 25◦C.
C. elegans-B. pseudomallei Survival
Assay
All assays involving B. pseudomallei were standardized according
to Ooi et al. (2012). To prepare the bacterial lawn, a single colony
of B. pseudomallei was inoculated into brain–heart infusion
(BHI) medium and grown for 16 h at 37◦C at 250 rpm. The
overnight culture was spread on NGM agar plates and incubated
at 37◦C for 24 h. Assay plates were then equilibrated to room
temperature for another 24 h. For the survival assay, 120 age-
matched RNAi-treated adult worms were transferred onto the
bacterial lawn (40 worms/plate) and incubated at 25◦C. Worm
mortality was scored over time and a worm was considered
dead when it was unresponsive to touch with the platinum
wire picker. In all experiments, bacteria containing an empty
RNAi expression vector (L4440) served as the control. Statistical
Kaplan–Meier non-parametric survival analysis was performed
using StatView (version 5.0.1; SAS Institute). At least two
independent experiments were performed.
Lifespan Assay
Lifespan assays were carried out as previously described (Lee
et al., 2013). Briefly, 120 age-matched adult worms were
transferred onto NGM agar plates containing 100 µg/ml
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kanamycin pre-seeded with E. coli OP50, which were exposed
overnight to 400 µg/ml kanamycin. Bacteria containing the
empty RNAi expression vector (L4440) served as the control.
Worm survival was enumerated daily and worms that died
due to bursting vulva were censored from further analysis.
Statistical Kaplan–Meier non-parametric survival analysis was
performed using StatView (version 5.0.1; SAS Institute). At least
two independent experiments were performed.
Peptide Synthesis
All peptides were synthesized using standard 9-fluorenylmethy
loxycarbonyl solid phase synthesis (Selleck Chemicals, USA).
The peptides were ≥90% pure as confirmed by analytical high-
performance liquid chromatography and mass spectrometry.
Stock solutions were prepared by dissolving each peptide powder
in the solution containing 0.01% (v/v) acetic acid and 0.2% (w/v)
bovine serum albumin. Subsequent dilutions were made in test
medium and prepared fresh in all experiments.
Biochemical Properties and Sequence
Analysis
The biochemical characteristics for each peptide were predicted
using the Antimicrobial Peptide Database1 (Wang et al., 2009).
Prediction of secondary structure was performed using JPred 32
(Cole et al., 2008). Specific regions predicted to form alpha helices
were subjected to helical wheel analysis using Heliquest3 (Gautier
et al., 2008). Atomic structure of peptides was visualized in Jmol
v. 13.0 (Herraez, 2006). Spatial orientation of peptides relative to
the membrane utilizing the three-dimensional structure program
was calculated in the PPM 2.0 server4 (Lomize et al., 2012).
Antimicrobial Susceptibility Test
The broth microdilution test was performed on a panel of
bacteria (B. pseudomallei Human R15, P. aeruginosa PA14,
S. typhimurium SL1344, S. aureus NCTC8325-4, MRSA ATCC
33591 and E. faecalis V583) according to the method outlined
by the Clinical and Laboratory Standards Institute (CLSI) M07-
A9 (Wiegand et al., 2008; CLSI, 2012). Briefly, a single bacterial
colony was inoculated into the respective medium supplemented
with an appropriate antibiotic (Table 1) and grown overnight
at 37◦C. The overnight culture was centrifuged to remove the
supernatant containing selective antibiotics and the pellet was
washed with fresh antibiotic-free medium twice. An aliquot
of the bacteria suspension was further diluted 1:100 in fresh
medium and grown until an OD600 = ∼0.5 was reached.
The bacterial inoculum size was standardized to approximately
5 × 105 CFU/ml by adjusting the optical density of the bacterial
suspension. Serial two-fold dilutions of each peptide were
prepared and added into wells of a microtiter plate containing
the respective bacterial inoculums. In parallel, two wells with
peptide-free medium were used as sterility and growth controls.
Plates were incubated at 37◦C for 18 h without shaking and
1http://aps.unmc.edu/AP/main.php
2http://www.compbio.dundee.ac.uk/jpred/index.html
3http://heliquest.ipmc.cnrs.fr/cgi-bin/ComputParams.py
4http://opm.phar.umich.edu/server.php
TABLE 1 | Selective medium for bacteria.
Bacterial strain Selective medium
Burkholderia pseudomallei Human R15 BHI agar/broth with gentamycin
(4 µg/ml)
Pseudomonas aeruginosa PA14 King’s B agar/broth with rifampicin
(100 µg/ml)
Salmonella typhimurium SL1344 LB agar/broth with streptomycin
(50 µg/ml)
Staphylococcus aureus NCTC8325-4 TS agar/broth with nalidixic acid
(15 µg/ml)
MRSA ATCC 33591 TS agar/broth with nalidixic acid
(15 µg/ml)
Enterococcus faecalis V583 BHI agar/broth with chloramphenicol
(25 µg/ml)
read with a microplate spectrophotometer at 630 nm. The MIC
endpoint reported is the lowest concentration of peptide able
to inhibit the growth of the test organism by 50% (MIC50)
or 90% (MIC90) compared to the growth in control wells.
Percentage of growth inhibition was determined using the
following formula: [1 - (OD630 of peptide-treated culture/OD630
of growth control)] × 100% (Sherlock et al., 2010). Aliquots
from any well with no growth were spotted onto antibiotic-
supplemented selective medium agar (Table 1) to determine the
lowest concentration of the peptide that reduces viability of the
initial bacterial inoculum by ≥99.9% [the minimum bactericidal
concentration (MBC)]. Two independent replicates of duplicate
samples were performed for the experiment.
Time-Kill Assay
Approximately 5 × 105 CFU/ml bacterial cells were exposed to
each peptide at final concentrations of 0×MIC90, 1×MIC90, 2×
MIC90, 4× MIC90, and 8× MIC90. Reaction mixtures with and
without peptides were incubated at 37◦C for 0, 1, 2, 4, 8, and
24 h. At the indicated time points, aliquots were serially diluted
in 1× PBS. About 10 µl of each dilution was then spotted on
Ashdown agar supplemented with 4 µg/ml gentamycin using the
drop plate method with minor modification (Herigstad et al.,
2001). Agar plates were incubated at 37◦C for 48 h and visually
separate colonies were counted. A bactericidal effect was defined
as a ≥3 log10 reduction in CFU/ml compared with the initial
inoculum. The experiment was performed in duplicate.
SYTOX Green Assay
The interaction of peptides with B. pseudomallei was examined
using fluorescence microscopy and an assay based on the
uptake of the fluorescent dye SYTOX Green (Invitrogen, USA;
Matsumoto et al., 2010) with minor modifications. First, bacterial
cells at about 5 × 105 CFU/ml were treated with 8× MIC90
peptides for 1 h at 37◦C. The cells treated with 0.5% Triton
X-100 and 1× PBS were included as the controls. Bacterial
suspensions were then stained with 1 µM SYTOX green and
incubated for 30 min at room temperature in the dark. An
aliquot of the reaction mixtures was spotted onto a glass slide for
visualization at 200× magnification under the Leica DM5000B
upright microscope equipped with a GFP2 filter cube (bandpass
480/40 nm). Three independent replicates were performed.
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DNA Binding Assay
This test evaluates the presence of peptide-DNA binding by
noting the retardation of the rate of migration of DNA bands
through agarose gels as previously described (Yan et al., 2013).
Briefly, 500 ng of pUC19 plasmid DNA (Invitrogen, USA)
was mixed with individual peptides (to final concentrations of
between 0.5 and 1024 µM) in 30 µl of 10 mM Tris-HCl, 1 mM
EDTA buffer, pH 8.0. Reaction mixtures were incubated at room
temperature for 30 min and subsequently electophoresed on 1%
agarose gel. The experiment was performed in triplicate.
Bacterial Filamentation Assay
Bacterial cell morphology was examined to assess if the peptides
cause filamentation of B. pseudomallei cells, indicative of
inhibition of in vivo DNA synthesis (Alfred et al., 2013). About
5× 105 CFU/ml bacterial suspension was exposed to each peptide
at 8× MIC90. Bacterial cells treated with 1× PBS were used as
the negative control. After 1 h incubation at 37◦C, an aliquot
of the reaction mixture was spotted onto a microscope slide,
air dried and stained with crystal violet for 1 min. Excess stain
was subsequently rinsed off using distilled water and air-dried.
All samples were observed using the Leica DM5000B upright
microscope (1000× magnification). Each image was captured
using identical settings and the experiment was performed in
triplicate.
Cytokine Measurement
This experiment was conducted according to the protocol
described by Thivierge et al. (2013) with modifications. Briefly,
∼2 × 105 cells/well early passage RAW264.7 cells were treated
with peptides (0.5 µM each) for 1 h at 37◦C. Untreated cells
served as the negative control. Cells were washed with 1× PBS
and subsequently infected with B. pseudomallei at a MOI of 10:1
for an additional 4 h. Cell culture supernatants were harvested
and inflammatory cytokines were measured with the multi-
analyte ELISArray kit (QIAGEN, Germany). The experiment was
performed in duplicate.
Cytotoxicity Assay
The cytotoxicity of peptides on mammalian cells was examined
as described (Thivierge et al., 2013) with minor modifications.
In brief, approximately 2 × 105 cells/well early passage murine
macrophage RAW264.7 cells were treated with 0, 2.5, 5, 10, 25, 50,
75, 100, 200, and 300 µM peptides for 1 h at 37◦C with 5% CO2.
The culture supernatants were collected and assayed for lactate
dehydrogenase (LDH) activity using the CytoTox LDH release kit
(Promega, USA). The amount of LDH released was expressed as
a percentage relative to the total amount of LDH released from
cells treated with lysis buffer. At least two independent replicates
were performed for the experiment.
Statistical Analysis
The survival between RNAi-treated and untreated worms was
assessed by the Log-rank (Mantel–Cox) test using StatView
(version 5.0.1; SAS Institute). For the other assays, data were
expressed as mean± standard error of the mean (SE) from at least
two independent assays. Statistical analysis was performed using
the unpaired, two-tailed Student’s t-test. The p-value of <0.0001
was considered as statistically significant.
RESULTS
Identification of Short Peptides Required
for Worm Protection against B.
pseudomallei
In a previous study we analyzed the genome-wide transcriptome
of C. elegans following B. pseudomallei infection (Lee et al., 2013).
With the availability of the expression profile, we screened for
AMP-like genes that fulfilled the criteria of typical AMPs: (i)
genes predicted to encode a peptide of less than 150 amino
acids and (ii) carry a signal peptide sequence as determined by
signalP 4.0 (Nielsen et al., 1997). The screen identified 36 putative
AMP-encoded genes as listed in Table 2. To interrogate whether
these candidate genes encode peptides that confer protection
against the pathogen, 34 of the 36 predicted AMP-encoding
genes were individually knocked down in rrf-3(pk1426);glp-4(bn)
worms by RNAi feeding and mutant worms were challenged
with B. pseudomallei. The rrf-3(pk1426) mutation improves
RNAi efficiency (Simmer et al., 2002) whilst the glp-4(bn)
mutation resulted in the development of sterile adults lacking
germ line proliferation, thus eliminating any confounding
effects of progeny during infection and analysis (Beanan
and Strome, 1992). If these putative AMP-encoded genes are
required to protect the worm against B. pseudomallei infection,
inactivating the genes should present an enhanced susceptibility
to pathogen-induced killing (Esp) phenotype. Worms abrogated
for the F32G8.3, F45E4.5, hrg-3, ttr-21, F17E9.3, F59A7.2, nlp-
27, ssp-37, F26F12.5, F33D11.8, nlp-31, and Y43C5A.3 genes
were hypersensitive to infection relative to the vector control
(p < 0.0001; Figures 1A–C; Supplementary Table 2), suggesting
that these 12 genes may be involved in the worm antimicrobial
response. This set of candidate genes includes nlp-27 (Figure 1B)
and nlp-31 (Figure 1C), two representative members of the
structurally related neuropeptide-like proteins (NLPs) family of
C. elegans AMPs. Abrogation of the remaining 22 candidate genes
did not lead to a significant difference in nematode survival
(p > 0.0001; Supplementary Figure 1). These 22 genes include
other NLP members, i.e., nlp-25 (Supplementary Figure 1A),
nlp-29 (Supplementary Figure 1D) and nlp-30 (Supplementary
Figure 1D) whereby RNAi knockdown of the corresponding
gene did not alter worm survival during the B. pseudomallei
infection compared to the control (p> 0.0001). This could reflect
a redundancy in the function of these NLP members because
often, other members of multi-gene families may compensate for
loss of the targeted member.
To confirm that the Esp phenotype is mediated by infection
rather than a consequence of loss of fitness, we silenced these
12 genes individually by RNAi and subsequently assessed worm
longevity under normal growth conditions. As E. coli OP50
grown on BHI medium is pathogenic to C. elegans (Garsin et al.,
2001), worms were fed with antibiotic-killed bacteria on NGM
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TABLE 2 | Putative AMP-encoded genes.
No. Gene ID Gene
name
Fold
changea
Size (amino
acid)
Signal
peptide
1 B0213.2 nlp-27 1.35 72 Yes
2 B0213.4 nlp-29 3.34 73 Yes
3 B0213.5 nlp-30 2.25 69 Yes
4 B0213.6 nlp-31 2.72 75 Yes
5 B0334.1 ttr-18 1.59 139 Yes
6 C01G10.4 1.24 72 Yes
7 C01G10.5 1.26 75 Yes
8 C23G10.11 0.62 63 Yes
9 C45B2.1 1.45 101 Yes
10 C45B2.2 1.54 99 Yes
11 D2007.1 1.99 111 Yes
12 F09F3.6 ttr-21 1.42 145 Yes
13 F10D7.3 2.49 146 Yes
14 F17E9.3 1.48 139 Yes
15 F26F12.5 1.53 118 Yes
16 F32G8.3 1.82 129 Yes
17 F33D11.8 1.12 85 Yes
18 F41E7.4 fip-5 1.97 74 Yes
19 F45E4.5 2.14 108 Yes
20 F55B11.4 2.07 145 Yes
21 F58E6.7 2.26 70 Yes
22 F58H10.1 2.38 119 Yes
23 F59A7.2 2.03 116 Yes
24 K04F1.9 4.09 139 Yes
25 K07A1.6b 1.77 100 Yes
26 R05A10.4 1.31 112 Yes
27 R09B5.9 cnc-4 2.79 66 Yes
28 T08A9.2b ttr-30 2.65 143 Yes
29 W02D9.5 ssp-37 1.42 112 Yes
30 Y43C5A.3 1.62 108 Yes
31 Y43F8C.1 nlp-25 0.81 87 Yes
32 Y46E12A.1 cnc-6 5.18 98 Yes
33 Y51A2D.11 ttr-26 4.06 144 Yes
34 Y5F2A.2 ttr-17 3.26 131 Yes
35 ZK1307.2 1.73 127 Yes
36 ZK970.7 4.31 147 Yes
aFold change relative to uninfected worms at early time point (4 h post-infection;
Lee et al., 2013). bOf the 36 putative AMP-encoded genes, RNAi clones were
available for 34 genes and not available for K07A1.6 and T08A9.2.
agar plates. We confirmed that the observed Esp phenotype was
not due to a decrease in worm fitness as the putative AMP-
RNAi-treated worms survived as long as the control (p> 0.0001;
Supplementary Figures 2A–C). Hence, we assume that these
12 genes may potentially encode peptides with antimicrobial
property. These genes were then chemically synthesized and
used for all subsequent characterization. Peptide sequences and
their biochemical characteristics are presented in Supplementary
Table 1.
Antimicrobial Activity of Synthetic Peptides
The susceptibility of B. pseudomallei to these synthetic
peptides (0.25–128 µM) was evaluated through a preliminary
microdilution test. To avoid non-specific binding of peptides
to the wall of the 96-well plates, polypropylene microtiter
plates were used. The control used was the well-described
human cathelicidin LL-37 with reported antimicrobial effect
on B. pseudomallei (Kanthawong et al., 2009). Of the peptides
tested, only LL-37, NLP-31, and Y43C5A.3 exhibited anti-
B. pseudomallei activity in a dose-dependent manner with
50% bacterial growth inhibition at 128 µM (Figure 2). No
pronounced antimicrobial effect was observed for the other
peptides. Next, we asked if these two anti-B. pseudomallei
peptides exert broad spectrum antimicrobial activity. These
antimicrobial effects of NLP-31 and Y43C5A.3 at concentrations
ranging from 2 to 1024 µM were further evaluated against a
panel of bacteria. Both peptides exhibited antimicrobial activity
against all tested microorganisms (Table 3), albeit with a more
pronounced preference for Gram-negative bacteria.
To examine the influence of helicity and amphipathicity on
peptide killing activity, peptide structures were predicted
followed by subjecting regions containing α-helices to
amphipathicity analysis. Both LL-37 and Y43C5A.3 adopted
helical structures whilst NLP-31 was in an extended
conformation (Figure 3A). The amphipathicity of the helical
regions for LL-37 and Y43C5A.3 was examined by Heliquest
(Gautier et al., 2008). Hydrophobic moment (µH) is used
to measure the amphipathicity of a helix and if the value is
greater than 0.5, the more likely the α-helical structure will be
amphipathic. We found that the helical region of LL-37 (residues
3–30) was clearly amphipathic (µH: 0.629); however, residues
68–80 of Y43C5A.3 were arranged in a non-amphipathic
conformation (µH: 0.084; Figure 3B). These findings could
explain the reduced killing efficacy for both nematode peptides
relative to the amphipathic α-helix LL-37 because low helix
propensity could lead to a concomitant reduction in antibacterial
activity (Nielsen et al., 2007).
Mode of Action of NLP-31 and Y43C5A.3
To examine the B. pseudomallei killing kinetics for NLP-31 and
Y43C5A.3, bacterial cells were exposed to both peptides at 0×
MIC90, 1× MIC90, 2× MIC90, 4× MIC90, and 8× MIC90 for
various time points before determining the number of surviving
bacteria at each time point. Figure 4 depicts the time-kill kinetics
of NLP-31 and Y43C5A.3 against B. pseudomallei. A reduction in
cell viability was observed for cells treated with 8×MIC90 of LL-
37 within the first 30 min (Figure 4A). Complete killing (≥3log10
drop in CFU/ml) was achieved 2 h post-treatment, further
supporting the finding that LL-37 possesses bactericidal activity
against B. pseudomallei (Kanthawong et al., 2012). Conversely,
NLP-31 (Figure 4B) and Y43C5A.3 (Figure 4C) exhibited a
bacteriostatic effect on B. pseudomallei for the first 4–8 h after
incubation.
To determine if both peptides interact with the bacterial
membrane, an in silico approach was used whereby the
peptide spatial orientation relative to the inner membrane
was calculated using the PPM 2.0 program (Lomize et al.,
2012; Figure 5A). Modeling of nematode peptide binding on
the simulated lipid membrane illustrated that LL-37 inserted
deeply into the hydrophobic membrane core (to a depth of
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FIGURE 1 | Functional assessment of putative AMP-encoding gene contribution on worm survival using RNAi feeding. A time-course of Burkholderia
pseudomallei infection on RNAi-treated worms was compared to the control. (A–C) RNAi-inactivation of candidate genes resulted in an enhanced worm
susceptibility to pathogen killing. In a pair-wise comparison to control worms using log-rank tests, the difference is significant (∗∗∗p < 0.0001). The graph depicts the
mean ± SD of three replicates (40 worms/replicate; n = 120) from a representative of two independent assays.
8.6 ± 0.1 Å) whilst NLP-31 and Y43C5A.3 spanned the
membrane at a depth of 2.6 ± 1.8 and 2.5 ± 0.9 Å, respectively.
The SYTOX green uptake assay was also conducted to study
the effects of NLP-31 and Y43C5A.3 on B. pseudomallei
membrane integrity. This nucleic acid stain is not able to
permeate live intact cells, however, if the cell membrane is
compromised, the dye binds to DNA as visualized by cytoplasmic
fluorescence. No fluorescence was observed in untreated bacteria
whilst cells treated with Triton X-100 fluoresced (Figure 5B).
Similarly, the LL-37 peptide caused an influx of dye into the
cytoplasm and SYTOX-stained fluorescent cells were observed
corresponding to the earlier report that LL-37 is able to
disrupt the membrane of B. pseudomallei (Kanthawong et al.,
2012). On the other hand, no fluorescence was observed in
cells exposed to NLP-31 and Y43C5A.3 proposing that both
these peptides adopted a non-membranolytic mode of action.
The different mode of action for LL-37 and the nematode
peptides is also supported by the accelerated killing kinetics
of LL-37 as peptides with better membrane permeability
exhibit faster inhibition of bacterial growth (Madhongsa et al.,
2013).
It is known that some AMPs translocate into the cytoplasm
without causing any membrane damage and bind intracellular
targets (e.g., DNA), leading to cellular inactivation (Jang et al.,
2010). Thus, we investigated the DNA-binding properties of
peptides using the gel retardation assay. A fixed amount of
supercoiled pUC19 plasmid DNA was mixed with different
amounts of peptides and electrophoresed. Plasmid DNA exposed
to no peptides or peptides at low concentrations migrated
successfully into the gel (Figures 6A–C). At higher LL-37 peptide
concentrations (8 µM onward), DNA migration was completely
retarded (Figure 6A). NLP-31 was also able to retard DNA
migration from 32 µM onward (Figure 6B) whilst as much as
128 µM of Y43C5A.3 was required to inhibit migration of pUC19
(Figure 6C). The retardation of DNA migration is most likely
attributed to the formation of peptide-DNA complex, indicating
that these peptides could interact with DNA with varying affinity
and thereafter interfere with the viability of B. pseudomallei.
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FIGURE 2 | Anti-B. pseudomallei activity of synthetic peptides. The
graph depicts the percentage of bacterial growth inhibition for each peptide
at 18 h post-incubation. Results are expressed as mean ± SEM of two
individual assays (n = 4). Dashed line demarcates the 50% growth inhibition
(MIC50).
As AMPs may use multiple mechanisms of action to combat
pathogens (Lehrer et al., 1989; de Leeuw et al., 2010), we extended
our investigation to determine whether NLP-31 and Y43C5A.3
could inhibit replication in vivo by treating bacterial cells with the
peptides at 8×MIC90 for 1 h and inspecting their morphology by
light microscopy. As illustrated in Figure 7, the untreated control
bacteria appeared as blue rod-shaped individual cells whilst
the chain-forming phenotype (denoted by the red arrow) was
observed for cells treated with LL-37, NLP-31, and Y43C5A.3.
It is known that filamentation can be induced in E. coli if
antimicrobial agents inhibit bacterial DNA synthesis during cell
division causing the rod-shaped cells to continue to grow in
size but fail to divide (Lutkenhaus, 1990). Therefore, NLP-31
and Y43C5A.3 bind to DNA and this peptide-DNA complex
most likely interrupted the DNA synthesis machinery as reflected
by the formation of cellular filaments. Nevertheless, how these
peptides are internalized into the bacterial cells still remains
unresolved. TA
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FIGURE 3 | Secondary structure prediction for LL-37, NLP-31, and
Y43C5A.3. (A) Atomic structure of peptides are shown as cartoon diagrams
colored according to secondary structure (violet for α-helix, blue for turns,
white for unstructured) and images were produced using Jmol. (B) Helical
wheel projections for LL-37 (residues 3–30) and Y43C5A.3 (residues 68–80)
were generated using Heliquest. Arrows indicate relative hydrophobic
moment, a measure of the amphipathicity of peptides in α-helical
conformation.
FIGURE 4 | Killing kinetics of synthetic peptides against
B. pseudomallei. Bacterial suspensions were treated with (A) LL-37,
(B) NLP-31 and (C) Y43C5A.3 at 0× MIC90 (#), 1× MIC90 (), 2× MIC90
(N), 4× MIC90 (×) and 8× MIC90 () and CFU/ml was enumerated at
indicated time points. Untreated bacterial suspension was included as the
control. A bactericidal effect was defined as a ≥3 log10 reduction in CFU/ml
compared with the initial inoculum. Data are the mean ± SEM of two
independent experiments performed in triplicate (n = 6).
Modulation of Inflammatory Cytokines
by NLP-31 and Y43C5A.3
Acute forms of melioidosis generally lead to sepsis and death,
both of which are most likely a result of an uncontrolled
inflammatory reaction (Gan, 2005). As inflammatory processes
are mediated by cytokines, we measured cytokine production in
B. pseudomallei infected murine macrophage RAW264.7 cells.
FIGURE 5 | NLP-31 and Y43C5A.3 do not act against B. pseudomallei
by disrupting the cell membrane. Spatial orientation of peptides relative to
a simulated membrane were predicted using PPM 2.0 program and validated
using the SYTOX green assay. (A) Membrane binding models of LL-37,
NLP-31, and Y43C5A.3 are shown as cartoon diagrams colored according to
secondary structure (violet for α-helix, blue for turns, white for unstructured);
the hydrophobic membrane boundary (at the level of the lipid carbonyls) is
represented by gray dots. Images were produced using Jmol.
(B) Representative fluorescence microscopy showing images of
B. pseudomallei cells treated with 1× PBS (untreated control), 0.5% Triton
X-100, 8× MIC90 LL-37, 8× MIC90 NLP-31, and 8× MIC90 Y43C5A.3.
FIGURE 6 | DNA-binding ability of peptides. Interaction of (A) LL-37,
(B) NLP-31, and (C) Y43C5A.3 with 500 ng of pUC19 plasmid DNA was
assessed by measuring the retardation of DNA migration on agarose gels. The
number above each lane denotes the concentration of synthetic peptides.
Lane M contains the supercoiled DNA ladder.
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FIGURE 7 | Morphology of B. pseudomallei cells treated with peptides.
Bacterial cells were mixed with individual peptides at 8× MIC90 for 1 h at
37◦C and observed using light microscopy at 1000× magnification under oil
emersion. Representative micrographs of bacteria cells treated with 1× PBS
(untreated control), LL-37, NLP-31, and Y43C5A.3 are shown. Red arrow
denotes the chain-forming phenotype in B. pseudomallei cells.
We noted that the pro-inflammatory cytokines tumor necrosis
factor alpha (TNF-α), interleukin (IL)-12, IL-1β and interferon
gamma (IFN-γ) were markedly induced upon infection whilst
IL-1α, IL-1β, IL-2, IL-4, IL-6, IL-10, IL-17A and granulocyte-
macrophage colony-stimulating factor (GM-CSF) were barely
detectable (Figure 8A). This observation was similar to that
previously reported by Chiang et al. (2015).
In this study, murine macrophage RAW264.7 cells were pre-
treated with 0.5 µM LL-37, NLP-31 or Y43C5A.3 prior to
B. pseudomallei infection and the peptide effect on cytokine
production was determined. The peptide concentration of
0.5 µM was selected based on the reported physiological
concentration for human cathelicidin LL-37 (0.44 µM; Lai and
Gallo, 2009). We observed that the levels of TNF-α (Figure 8B)
and IL-12 (Figure 8C) secreted by peptide-treated infected
cells were suppressed (p < 0.0001) relative to the untreated
control cells whereas production of IL-1β (Figure 8D) and
IFN-γ (Figure 8E) remained unchanged. TNF-α and IL-12
are typically pro-inflammatory cytokines and therefore, the
observed suppression of these cytokines implies that NLP-
31 and Y43C5A.3 may regulate inflammation during sepsis.
Moreover, G-CSF (Figure 8F) and IL-6 (Figure 8G) were
induced significantly in NLP-31 and Y43C5A.3 pre-treated cells
as compared to the untreated control (p< 0.0001). The detection
of elevated levels of these cytokines in response to B. pseudomallei
infection further support the potential application of NLP-31 and
Y43C5A.3 as anti-inflammatory molecules.
NLP-31 and Y43C5A.3 Are Not Cytotoxic
to Mammalian Cells
For AMPs to enter clinical development, it is critical that
the peptides are not toxic to the host. We observed that
the macrophage cells are vulnerable to ≥25 µM of LL-37
(Figure 9), similar to the findings of Thivierge et al. (2013).
In comparison, NLP-31 and Y43C5A.3 only exhibited low
cytotoxic effects at all the test concentrations up to 300 µM.
Moreover, macrophage morphology was normal as observed by
light microscopy compared to the shriveled and disrupted LL-
37 treated cells (data not shown). LL-37 is more hydrophobic
than NLP-31 and Y43C5A.3 (Supplementary Table 1) and it has
been established that peptides with greater hydrophobicity are
more likely to be toxic to mammalian cells (Bessalle et al., 1993).
These nematode peptides with minimal toxicity on eukaryotic
cells are ideal candidates for further evaluation as a potential
therapeutics.
DISCUSSION
The growing threat of antibiotic-resistant B. pseudomallei and
the limited arsenal of antibacterial agents for melioidosis therapy
highlight the search for alternative therapeutics. AMPs are good
anti-bacterial candidates because the probability that the bacteria
will develop resistance is less likely compared to conventional
antibiotics (Peschel and Sahl, 2006). A good example of an AMP
with limited resistance is nisin, a food preservative which has
been used for nearly 60 years (Shin et al., 2015). B. pseudomallei
is inherently resistant to AMPs such as protamine sulfate, human
neutrophil peptide (HNP-1), and polymyxin B (Jones et al.,
1996; Burtnick and Woods, 1999). This Gram-negative bacterium
employs diverse mechanisms to resist killing by antimicrobial
agents, including exclusion from the cell, eﬄux from the cell,
enzymatic inactivation, and alteration of target sites (Schweizer,
2012; Bahar and Ren, 2013). Nevertheless, the search for AMPs
toward B. pseudomallei is being pursued.
Taking advantage of the availability of nematode gene
expression data of B. pseudomallei-infected worms (Lee et al.,
2013), we set out to identify potential nematode AMPs that
kill this pathogen. From an initial selection of 36 putative
AMP-like genes chosen from the microarray data, a RNA-
inhibition screen allowed us to confirm 12 (35%) of these
genes as essential to protect the worm against a B. pseudomallei
infection. Among these, NLP-31 is the only experimentally
proven AMP with antibacterial activity against Gram-positive
Micrococcus luteus and Gram-negative E. coli (Couillault et al.,
2004). Here, we demonstrated that both NLP-31 and Y43C5A.3
inhibit B. pseudomallei growth in a dose-dependent manner.
This is the first report on the potential antibacterial property of
Y43C5A.3 and more importantly, the ability of both peptides
to inhibit B. pseudomallei. Previously, Madhongsa et al. (2013)
reported that low concentrations (5–20 µM) of bactenecin, CA-
MA, RTA3 and BMAP-18 were able to inhibit the growth of
B. pseudomallei whilst Kanthawong et al. (2012) showed that
100 µM of LL-37 or LL-31 was required for equivalent activity.
In our hands, LL-37 inhibited bacterial growth by 90% (MIC90)
at 256 µM and bactericidal activity was observed within 2 h at
8× MIC90. Whilst the previous studies on the effect of LL-37
toward B. pseudomallei did not report an experimentally derived
MIC value (Kanthawong et al., 2012; Madhongsa et al., 2013),
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FIGURE 8 | Peptides modulate the release of pro- and anti-inflammatory cytokines upon B. pseudomallei infection. (A) When challenged with
B. pseudomallei, elevated levels of several inflammatory cytokines like TNF-α, IL-12, IL-1β, and IFN-γ were detected in infected murine macrophage RAW264.7 cells.
However, in the presence of peptides, the secretion of (B) TNF-α and (C) IL-12 by infected cells was significantly suppressed (p < 0.0001) whereas the levels of
(D) IL-1β and (E) IFN-γ remained unchanged. Conversely, unlike LL-37, both nematode peptides significantly induced (F) G-CSF and (G) IL-6. The data shown are
mean ± SEM of two independent experiments (n = 4). ∗∗∗Significant difference between untreated and treated cells (p < 0.0001).
the differences between all three studies could be attributed to
differences in the isolates tested and experimental conditions
used.
Amongst the microorganisms tested in this study,
P. aeruginosa PA14 showed relatively high susceptibility to the
control peptide LL-37 with an MIC50 value of 4 µM (18 mg/L).
Neidig et al. (2013) also demonstrated that the MIC value of
LL-37 against this bacterial strain was ∼3.56 µM (10 mg/L). In
addition, the MIC50 value for LL-37 on S. typhimurium SL1344
(64 µM, this study) was comparable to that reported by Shprung
et al. (2012; >50 µM). AMPs target a wide range of pathogenic
bacteria (Gottlieb et al., 2008). Here, we demonstrated that
NLP-31 and Y43C5A.3 were capable of exerting broad spectrum
antimicrobial activities, with higher selectivity toward Gram-
negative bacteria. This is likely due to the difference in outer
membrane composition between Gram-positive and Gram-
negative bacteria as proposed by Torcato et al. (2013). We
also note that the MIC values for B. pseudomallei are several
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FIGURE 9 | Nematode peptides are not cytotoxic to mammalian cells. Murine macrophage RAW264.7 cells were incubated with peptides for 1 h at 37◦C.
Release of LDH by cells was measured and expressed as the percentage of LDH released after treatment of cells with lysis buffer (regarded as 100%). The bars
correspond to the mean ± SEM of two independent experiments performed in triplicate (n = 6). ∗∗∗A significant difference between untreated and treated cells
(p < 0.0001).
magnitudes greater than for P. aeruginosa and S. typhimurium.
This may be attributed to the presence of biofilm or a different
type of LPS moiety for Burkholderia spp. (Loutet et al., 2011).
Over the past decade, a diverse array of putative AMPs has
also been identified based on their induced expression upon
infection or sequence similarities (Kato et al., 2002; Pujol et al.,
2008), however, the evidence for their biological function is still
not fully understood. This study provides information on how
the two putative nematode peptides (NLP-31 and Y43C5A.3)
exert effects on B. pseudomallei. The computational modeling
of peptide-membrane interaction predicted that the peptides are
able to traverse the cell membrane. Nevertheless, no influx of
SYTOX green into the cytoplasm was observed in the presence
of peptides, indicating that NLP-31 and Y43C5A.3 are non-
membrane acting. Although it is well-documented that most
AMPs act primarily by membrane disruption (Matsuzaki et al.,
1997), NLP-31 and Y43C5A.3 may be inhibiting B. pseudomallei
growth through a non-membrane permeabilization mechanism.
An alternative to membrane-acting peptides is AMPs that
interact with intracellular targets resulting in loss of viability
(Nicolas, 2009). For example, the frog AMP buforin II penetrates
E. coli without destabilizing the cell membrane and inhibits
cellular functions by binding to both DNA and RNA (Park
et al., 1998). Collectively, we propose that NLP-31 and Y43C5A.3
do not disrupt the bacterial membrane but in turn, interact
with cytoplasmic macromolecules to interfere with bacterial
viability. This suggestion is supported by the gel retardation
assay profile where both peptides were able to bind to DNA
and this peptide-DNA complex most likely interrupted the DNA
synthesis machinery as reflected by the formation of cellular
filaments. The peptides amino acid sequences indicated that both
NLP-31 and Y43C5A.3 are glycine/tyrosine-rich peptides. The
abundance of glycine and tyrosine may explain the peptides’ DNA
binding property. Glycine is a small amino acid with a single
hydrogen atom as its side chain could bind to the phosphate
moiety on DNA (Schulze-Gahmen et al., 1996). In addition,
tyrosine residues can interact with DNA either by hydrophobic
interactions via stacking with DNA bases or by hydrogen bonding
with the nucleotide through the phenolic OH group (Dimicoli
and Helene, 1974).
In addition to direct microbial killing activity,
immunomodulatory effects have also been ascribed to
AMPs (Afacan et al., 2012). The importance of peptides in
defense against infections is partly reflected by their ability
to regulate cytokines in macrophage cells. Consistent with
this concept, Scott et al. (2002) demonstrated that LL-37
suppressed the LPS-stimulated induction of TNF-α, offering
protection in an experimental endotoxemia mouse model.
Furthermore, two synthetic AMPs that were developed based
on the bovine bactenecin, IDR-1 and IDR-1002, suppressed
specific pro-inflammatory cytokines such as TNF-α whilst
concomitantly enhancing anti-inflammatory effects (Nijnik
et al., 2010). Here, we investigated the potential of NLP-31 and
Y43C5A.3 in regulating the inflammatory response triggered by
B. pseudomallei. Both peptides markedly suppressed the pro-
inflammatory cytokines, including TNF-α whilst inducing the
anti-inflammatory cytokines. Thus, it is plausible that NLP-31
andY43C5A.3 promote localized immunity to infection whilst
preventing the damaging systemic hyperinflammatory response
observed in melioidosis patients.
When a melioidosis infection is diagnosed, treatment
with appropriate antibiotic therapy is initiated. In general,
bacteriostatic agents may be used in the eradication phase of
the melioidosis treatment protocol (Inglis, 2010). Although,
bactericidal drugs with rapid killing effects offer better clinical
outcome, the available evidence suggests that bacteriostatic
drugs may be more advantageous for certain infections such
as Streptococcal toxic shock syndrome (Pankey and Sabath,
2004). We show that NLP-31 and Y43C5A.3 are bacteriostatic
toward B. pseudomallei only over the first 4–8 h post-incubation.
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We suggest that these peptides may be effective if used
in combination with antibiotics in the eradication phase of
melioidosis treatment at a point when the infected host
immune response is strong enough to eliminate the non-
replicating bacteria. Recently, Randhawa et al. (2016) have
elegantly demonstrated the potential of a cell-penetrating peptide
in combination with antibiotic therapy to combat bacterial
infection. The cell-penetrating ability and low toxicity of NLP-
31 and Y43C5A.3 reported in this study proposes a similar
combination of antibiotics and AMPs for melioidosis treatment.
This combination therapy may offer an advantage in minimizing
antimicrobial resistance, reducing toxic side effects and providing
synergistic interaction between the antimicrobial agents (Feng
et al., 2015). The peptides efficacy against B. pseudomallei can be
further evaluated through in vivo antibacterial and toxicity effects
in infected mice.
CONCLUSION
We have identified two C. elegans peptides, NLP-31 and
Y43C5A.3, that exhibited modest antimicrobial activity against
B. pseudomallei by interfering with bacterial DNA synthesis
and in parallel, showed some promise in modulating host
cytokine production to dampen the inflammatory response
during infection. The in vivo role of these peptides is definitely
more complex and may involve immuno-modulation, anti-
inflammatory or other host-directed effects rather than direct
anti-bacterial effects. Further modifications of these synthetic
peptides could possibly lead to enhanced anti-B. pseudomallei
activities. The non-toxic nature of these peptides toward human
macrophage cells urges the evaluation of these AMPs for possible
clinical use, particularly against antibiotic-resistant pathogens
like B. pseudomallei.
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